





Broad Oncology Pipeline with a Focus on ADC

Modality	Program	Indication	Preclinical	Ph 1	Ph 2	Ph 3	Next Dev. Milestone
ADC	OBI-992 (TROP2 ADC via Cys conjugation)	Advanced Solid Tumors					Ph1 Readout
	OBI-902 (TROP2 ADC via GlycOBI®)					2025 US FDA IND TFDA IND Approved	Ph1 Readout
	OBI-904 (Nectin-4 ADC via GlycOBI®)						IND
	OBI-201 (TROP2x HER2 BsADC via GlycOBI®)	Undisclosed					IND
	Bispecific/ Dual Payload ADC (cMETx HER3 via GlycOBI®)						IND
Prodrug	OBI-3424 (AKR1C3 targeted prodrug)	Liver (HCC) [†] & T-ALL [‡]					Ph 2 Readout

GlycOBI® is a registered trademark of OBI Pharma Inc.

[†] Clinical study conducted by Asentawits (China)

[‡] Clinical study conducted by NIH-SWOG (US)